Abstract
Pantothenamides inhibit blood-stage Plasmodium falciparum with potencies (50% inhibitory concentration [IC50], ∼20 nM) similar to that of chloroquine. They target processes dependent on pantothenate, a precursor of the essential metabolic cofactor coenzyme A. However, their antiplasmodial activity is reduced due to degradation by serum pantetheinase. Minor modification of the pantothenamide structure led to the identification of α-methyl-N-phenethyl-pantothenamide, a pantothenamide resistant to degradation, with excellent antiplasmodial activity (IC50, 52 ± 6 nM), target specificity, and low toxicity.
| Original language | English |
|---|---|
| Pages (from-to) | 3666-3668 |
| Number of pages | 3 |
| Journal | Antimicrobial Agents and Chemotherapy |
| Volume | 59 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 1 Jun 2015 |
Fingerprint
Dive into the research topics of 'A pantetheinase-resistant pantothenamide with potent, on-target, and selective antiplasmodial activity'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver